1688 completed, 288 terminated, 127 recruiting, 98 active not recruiting. 719 Phase 3, 676 Phase 2, 395 Phase 1, 364 Phase 4, 86 Not applicable.
Follow Sanofi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination - Immunization, Healthy Volunteers | Phase 3 | Not yet recruiting | Sanofi | 6000 | 2026-11-09 | 2026-10-22 |
| Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) Belumosudil, Ruxolitinib - cGVHD | Phase 2 | Not yet recruiting | Dennis Kim | 53 | 2026-11-01 | 2026-10-02 |
| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Acne mRNA (messenger ribonucleic acid) vaccine, Placebo - Acne | Phase 2 | Not yet recruiting | Sanofi | 410 | 2026-10-30 | 2026-09-18 |
| A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) Belumosudil - Chronic Graft Versus Host Disease | Phase 4 | Not yet recruiting | Sanofi | 26 | 2026-10-30 | 2026-10-23 |
| A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Duvakitug, Placebo - Hidradenitis | Phase 2 | Not yet recruiting | Sanofi | 156 | 2026-10-13 | 2026-10-14 |
| This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization dupilumab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 754 | 2026-10-06 | 2026-10-16 |
| Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China RSV AI-assisted primary care intervention - RSV Immunization | Not applicable | Not yet recruiting | Fudan University | 1500 | 2026-10-02 | 2026-10-13 |
| Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M - COVID-19 | Phase 4 | Recruiting | Sanofi | 660 | 2026-10-01 | 2026-10-15 |
| Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. Efluelda Tetra Pre-filled syringe - Immunization, Influenza (Healthy Volunteers) | Not yet recruiting | Sanofi | 670 | 2026-10-01 | 2025-12-15 | |
| An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition Rilzabrutinib, Rosuvastatin, Digoxin - Healthy Volunteer | Phase 1 | Active not recruiting | Sanofi | 14 | 2026-10-01 | 2026-10-21 |
| Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP) Intrahospital seasonal influenza vaccination offer, Standardized active influenza vaccination counseling, Standard of care discharge recommendation for ambulatory vaccination - Acute Coronary Syndrome, Heart Failure | Not applicable | Recruiting | Stephan Baldus | 482 | 2026-09-30 | 2026-10-13 |
| Effect of Messaging on Pragmatic Outcomes Within an Integrated Healthcare System Vaccine choice message, Vaccine choice + platform-framed message, Vaccine choice + HCP trust-framed message - Covid-19 Vaccination | Not applicable | Recruiting | Kaiser Permanente | 1300000 | 2026-09-29 | 2026-10-15 |
| Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function rilzabrutinib - Renal Impairment, Healthy Volunteers | Phase 1 | Recruiting | Sanofi | 16 | 2026-09-22 | 2026-10-23 |
| Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe Efluelda® Pre-filled syringe - Influenza Immunization, Healthy Volunteers | Recruiting | Sanofi | 670 | 2026-09-17 | 2026-10-20 | |
| A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) Lunsekimig - Chronic Obstructive Pulmonary Disease | Phase 3 | Enrolling by invitation | Sanofi | 1508 | 2026-09-16 | 2026-10-21 |
| Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older Bivalent RSV+HMPV protein vaccine, Placebo - Respiratory Syncytial Virus, Human Metapneumovirus | Phase 2 | Recruiting | Sanofi | 8000 | 2026-09-09 | 2026-10-19 |
| A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease Belumosudil, Best available therapy (BAT) - Chronic Graft Versus Host Disease | Phase 3 | Not yet recruiting | Sanofi | 356 | 2026-09-07 | 2026-09-15 |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA), Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) - Meningococcal Infection, Healthy Volunteers | Phase 3 | Recruiting | Sanofi | 4568 | 2026-08-22 | 2026-10-19 |
Showing 20 of 2345. Sign in to see all of them.
Diabetes Mellitus, Type 2 (238) · Diabetes Mellitus, Type 1 (86) · Neoplasms (86) · Diabetes Mellitus (80) · Breast Neoplasms (76) · Prostatic Neoplasms (72) · Dermatitis, Atopic (70) · Carcinoma, Non-Small-Cell Lung (56) · Asthma (55) · Colorectal Neoplasms (53) · Neoplasm Metastasis (51) · Hypercholesterolemia (50) · Multiple Myeloma (47) · Hypertension (36) · Atrial Fibrillation (35)
Docetaxel (174) · Insulin Glargine (170) · dupilumab (126) · Oxaliplatin (116) · Fluorouracil (65) · Metformin (63) · isatuximab (59) · insulin glulisine (57) · Cisplatin (55) · alirocumab (55) · cabazitaxel (52) · Capecitabine (51) · lixisenatide (49) · Dexamethasone (48) · Gemcitabine (44)
United States (1143) · France (514) · Canada (460) · Germany (449) · Spain (421) · Italy (360) · United Kingdom (320) · Poland (279) · Netherlands (266) · Brazil (264) · Belgium (254) · Australia (252) · Czechia (250) · Hungary (237) · Argentina (224)
Jaderson Lima (57) · Phyllis Diener (13) · Edibe Taylan (11) · Suman Wason, MD (11) · Jean-Philippe Aussel (8)
PMID 30183102, PMID 35636689, PMID 27777279, PMID 34298554, PMID 39588375, PMID 33166419, PMID 28964736, PMID 33023488, PMID 34037993, PMID 36723913, PMID 39963952, PMID 40993471, PMID 21716303, PMID 33078867, PMID 33165005, PMID 34037241, PMID 39899371, PMID 40207789, PMID 42546561, PMID 20844485, PMID 23146246, PMID 25006719, PMID 25117183, PMID 28391886, PMID 29974618, PMID 31066001, PMID 32348036, PMID 33453450, PMID 34142350, PMID 34519964, PMID 35567671, PMID 36413080, PMID 36808602, PMID 38770818, PMID 19348685, PMID 21836029, PMID 22429800, PMID 22435370, PMID 26872608, PMID 30160030, PMID 30366067, PMID 31407311, PMID 31424712, PMID 31956422, PMID 32453485, PMID 32522251, PMID 32907617, PMID 33337539, PMID 33481203, PMID 33710614
2023 (47), 2017 (41), 2016 (31), 2014 (23), 2025 (21), 2009 (20), 2015 (20), 2019 (20), 2008 (19), 2018 (19), 2005 (12), 2004 (3), P30CA138292 (2), 1UF1AG046143 (1), K23CA118431 (1)